ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray) [Yahoo! Finance]
ARS Pharmaceuticals, Inc. (SPRY)
Company Research
Source: Yahoo! Finance
biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the Opposition Division of the European Patent Office (the “EPO”) upheld the validity of all claims in EP 3678649, which is a patent validated in over 30 European countries directed to nasal spray epinephrine formulations including alkyl-glycoside, such as Intravail ® , and uses thereof. ARS Pharma's issued global intellectual property portfolio related to neffy provides coverage until at least 2039. Earlier this year, following successful defense of an Inter Partes Review (IPR) challenge and subsequent appeal proceedings, the United States Patent and Trademark Office formally upheld key claims for U.S. Patent No. 10,682,414, which is directed to methods of treating a type-1 hypersensitivity reaction, including anaphylaxis, using an epinephrine aqueous nasal spray. Thus, two different ARS Pharma
Show less
Read more
Impact Snapshot
Event Time:
SPRY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SPRY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SPRY alerts
High impacting ARS Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SPRY
News
- How Recent Developments Are Shaping the Story for ARS Pharmaceuticals According to Analysts [Yahoo! Finance]Yahoo! Finance
- ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswire
- ARS Pharmaceuticals (NASDAQ:SPRY) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.MarketBeat
- Why Analysts See the ARS Pharmaceuticals Story Shifting Amid Changing Growth and Market Risks [Yahoo! Finance]Yahoo! Finance
SPRY
Earnings
- 11/10/25 - Miss
SPRY
Sec Filings
- 11/14/25 - Form 4
- 11/14/25 - Form 4
- 11/14/25 - Form 4
- SPRY's page on the SEC website